Journal of Medicinal Chemistry · 2001 · 18 citations · 15 references
PharmacyMedicinal ChemistryPharmacologyCardiovascular PharmacotherapyDrug DesignDrug DiscoveryAntiarrhythmic TherapyCardiac Action PotentialsCardiac Ion ChannelsCardiovascular PharmacologyIon Channel PharmacologyLead Compound DesignAction Potential GenerationAction Potential PropagationAntiarrhythmic MedicationsAntiarrhythmic PharmacologyDelayed Rectifier Potassium CurrentsPotassium Channel BlockadePotassium Channel BlockersPotassium Channel Pharmacology
Multiple delayed rectifier potassium currents, including I(Ks), are responsible for the repolarization and termination of the cardiac action potential, and blockers of these currents may be useful as antiarrhythmic agents. Modification of compound 5 produced 19(S) that is the most potent I(Ks) blocker reported to date with >5000-fold selectivity over other cardiac ion channels. Further modification produced 24A with 23% oral bioavailability.
15
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome
Mark Curran, Igor Splawski, Katherine W. Timothy et al. · Cell · 1995 · 2.3K citations · Full text
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Benjamin F. Cravatt, Dan K. Giang, Stephen P. Mayfield et al. · Nature · 1996 · 2.1K citations
Coassembly of KVLQT1 and minK (IsK) proteins to form cardiac IKS potassium channel
Michael C. Sanguinetti, Mark Curran, Anruo Zou et al. · Nature · 1996 · 1.8K citations
KvLQT1 and IsK (minK) proteins associate to form the IKS cardiac potassium current
Jacques Barhanin, Florian Lesage, Eric Guillemare et al. · Nature · 1996 · 1.6K citations